



NDA 50-475/S-053

Pedinol Pharmacal, Inc.
Attention: Lance T. Moore, R.Ph., Esq.
30 Banfi Plaza North
Farmingdale, NY 11735

Dear Mr. Moore:

Please refer to your supplemental new drug application dated July 27, 2006, received July 28, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Gris-PEG[®] (griseofulvin ultramicrosized) Tablets, 125 mg and 250 mg.

This supplemental new drug application provides for labeling revisions related to the alternative administration of the drug product.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 50-475/S-053.**" Approval of this submission by FDA is not required before the labeling is used.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling text. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Margo Owens, Regulatory Project Manager, at (301) 796-2110.

Sincerely,

{See appended electronic signature page}

Susan Walker, M.D.
Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Susan Walker

1/24/2007 03:07:48 PM